These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36272282)

  • 1. Mechanisms of solid lipid nanoparticles-triggered signaling pathways in eukaryotic cells.
    Moraes-Lacerda T; de Jesus MB
    Colloids Surf B Biointerfaces; 2022 Dec; 220():112863. PubMed ID: 36272282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of solid lipid nanoparticles (SLN): the value of different alkyl polyglucoside surfactants.
    Keck CM; Kovačević A; Müller RH; Savić S; Vuleta G; Milić J
    Int J Pharm; 2014 Oct; 474(1-2):33-41. PubMed ID: 25108048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion of the helper lipid dioleoyl-phosphatidylethanolamine in solid lipid nanoparticles inhibits their transfection efficiency.
    de Jesus MB; Radaic A; Hinrichs WL; Ferreira CV; de Paula E; Hoekstra D; Zuhorn IS
    J Biomed Nanotechnol; 2014 Feb; 10(2):355-65. PubMed ID: 24738343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability.
    Oner E; Kotmakci M; Kantarci AG
    Pharm Dev Technol; 2020 Oct; 25(8):936-948. PubMed ID: 32315242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Lipids as Structural Components of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Topical Delivery.
    Dobreva M; Stefanov S; Andonova V
    Curr Pharm Des; 2020; 26(36):4524-4535. PubMed ID: 32410552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages.
    Schöler N; Olbrich C; Tabatt K; Müller RH; Hahn H; Liesenfeld O
    Int J Pharm; 2001 Jun; 221(1-2):57-67. PubMed ID: 11397567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.
    Garcês A; Amaral MH; Sousa Lobo JM; Silva AC
    Eur J Pharm Sci; 2018 Jan; 112():159-167. PubMed ID: 29183800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interfacial and colloidal characterization of oil-in-water emulsions stabilized by interface-tunable solid lipid nanoparticles.
    Lim H; Jo M; Ban C; Choi YJ
    Food Chem; 2020 Feb; 306():125619. PubMed ID: 31606630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of surfactant and lipid type on the physicochemical properties and biocompatibility of solid lipid nanoparticles.
    Pizzol CD; Filippin-Monteiro FB; Restrepo JA; Pittella F; Silva AH; Alves de Souza P; Machado de Campos A; Creczynski-Pasa TB
    Int J Environ Res Public Health; 2014 Aug; 11(8):8581-96. PubMed ID: 25141003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approach for overcoming the stability challenges of lipid-based excipients. Part 3: Application of polyglycerol esters of fatty acids for the next generation of solid lipid nanoparticles.
    Corzo C; Meindl C; Lochmann D; Reyer S; Salar-Behzadi S
    Eur J Pharm Biopharm; 2020 Jul; 152():44-55. PubMed ID: 32387704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability.
    Radomska-Soukharev A; Müller RH
    Pharmazie; 2006 May; 61(5):425-30. PubMed ID: 16724540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory and anti-cancer activity of citral: Optimization of citral-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®.
    Zielińska A; Martins-Gomes C; Ferreira NR; Silva AM; Nowak I; Souto EB
    Int J Pharm; 2018 Dec; 553(1-2):428-440. PubMed ID: 30385373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of linalool-loaded solid lipid nanoparticles using experimental factorial design and long-term stability studies with a new centrifugal sedimentation method.
    Pereira I; Zielińska A; Ferreira NR; Silva AM; Souto EB
    Int J Pharm; 2018 Oct; 549(1-2):261-270. PubMed ID: 30075252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
    Attama AA; Müller-Goymann CC
    Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.
    Doktorovova S; Souto EB; Silva AM
    Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid lipid nanoparticle (SLN) formulations as a potential tool for the reduction of cytotoxicity of saponins.
    Van de Ven H; Vermeersch M; Shunmugaperumal T; Vandervoort J; Maes L; Ludwig A
    Pharmazie; 2009 Mar; 64(3):172-6. PubMed ID: 19348339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the interplay between the TGF-
    Moraes-Lacerda T; Garcia-Fossa F; de Jesus MB
    Nanotechnology; 2024 May; 35(32):. PubMed ID: 38688253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.